BMJ1d
AB0146 HAND AND WRIST ACTIVE RANGE OF MOTIONS AND CONTRIBUTING FACTORS IN RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY
Background: Patients with rheumatoid arthritis (RA) usually impaired range of motions (ROMs), especially hand and wrist active ROMs (AROMs), thus influencing their ability to perform daily activities ...
BMJ2d
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ2d
Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis
Objectives The International League of Associations for Rheumatology classification criteria define systemic juvenile idiopathic arthritis (SJIA) by the presence of fever, rash and chronic arthritis.
BMJ3d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...
BMJ13d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ6d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ4d
Raised serum APRIL levels in patients with systemic lupus erythematosus
Objective: To determine whether serum levels of a proliferation-inducing ligand (APRIL) are raised in patients with systemic lupus erythematosus (SLE) and correlate with autoantibody titres or disease ...
BMJ12d
Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
BMJ7d
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Correspondence to Dr Laura C Cappelli, Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA; lcappel1{at}jhmi.edu Objective We sought to investigate the long-term outcomes of ...
BMJ11d
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
Objectives To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and ...
BMJ6d
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis
Background Juvenile idiopathic arthritis is one of the most prevalent chronic inflammatory diseases in children. Evidence suggests that early effective treatment minimises the burden of disease during ...
BMJ12d
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
1 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands Objectives Millions of patients worldwide are treated with therapeutic ...